WO2006058869A3 - Substituierte pteridine zur behandlung von entzündlichen erkrankungen - Google Patents

Substituierte pteridine zur behandlung von entzündlichen erkrankungen Download PDF

Info

Publication number
WO2006058869A3
WO2006058869A3 PCT/EP2005/056246 EP2005056246W WO2006058869A3 WO 2006058869 A3 WO2006058869 A3 WO 2006058869A3 EP 2005056246 W EP2005056246 W EP 2005056246W WO 2006058869 A3 WO2006058869 A3 WO 2006058869A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
treating inflammatory
substituted pteridines
pteridines
relates
Prior art date
Application number
PCT/EP2005/056246
Other languages
English (en)
French (fr)
Other versions
WO2006058869A8 (de
WO2006058869A2 (de
Inventor
Horst Dollinger
Domnic Martyres
Juergen Mack
Peter Nickolaus
Birgit Jung
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Horst Dollinger
Domnic Martyres
Juergen Mack
Peter Nickolaus
Birgit Jung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Horst Dollinger, Domnic Martyres, Juergen Mack, Peter Nickolaus, Birgit Jung filed Critical Boehringer Ingelheim Int
Priority to EP05823962A priority Critical patent/EP1824854A2/de
Priority to CA002587269A priority patent/CA2587269A1/en
Priority to JP2007541995A priority patent/JP2008521774A/ja
Publication of WO2006058869A2 publication Critical patent/WO2006058869A2/de
Publication of WO2006058869A3 publication Critical patent/WO2006058869A3/de
Publication of WO2006058869A8 publication Critical patent/WO2006058869A8/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Die Erfindung betrifft neue Pteridine, die geeignet sind zur Behandlung von • Atemwegs- oder gastrointestinalen Beschwerden oder Erkrankungen, • entzündlichen Erkrankungen der Gelenke, der Haut oder der Augen, • Erkrankungen des periphären oder zentralen Nervensystems oder • Krebserkrankungen, sowie pharmazeutische Zusammensetzungen die diese Verbindungen beinhalten.
PCT/EP2005/056246 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entzündlichen erkrankungen WO2006058869A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05823962A EP1824854A2 (de) 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entz]ndlichen erkrankungen
CA002587269A CA2587269A1 (en) 2004-11-29 2005-11-25 Substituted pteridines for treating inflammatory diseases
JP2007541995A JP2008521774A (ja) 2004-11-29 2005-11-25 炎症性疾患治療用の置換プテリジン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004057595.9 2004-11-29
DE102004057595A DE102004057595A1 (de) 2004-11-29 2004-11-29 Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen

Publications (3)

Publication Number Publication Date
WO2006058869A2 WO2006058869A2 (de) 2006-06-08
WO2006058869A3 true WO2006058869A3 (de) 2006-10-26
WO2006058869A8 WO2006058869A8 (de) 2007-01-18

Family

ID=36127308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/056246 WO2006058869A2 (de) 2004-11-29 2005-11-25 Substituierte pteridine zur behandlung von entzündlichen erkrankungen

Country Status (8)

Country Link
US (1) US7750009B2 (de)
EP (1) EP1824854A2 (de)
JP (1) JP2008521774A (de)
AR (1) AR054991A1 (de)
CA (1) CA2587269A1 (de)
DE (1) DE102004057595A1 (de)
TW (1) TW200635597A (de)
WO (1) WO2006058869A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057645A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057594A1 (de) * 2004-11-29 2006-06-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen
WO2007135026A2 (de) * 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Substituierte pteridine als therapeutika
US20090318456A1 (en) * 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
WO2008009079A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
AU2008319397B2 (en) 2007-11-01 2013-01-31 Acucela, Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
KR101756050B1 (ko) 2015-03-04 2017-07-07 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
AU2018357775B2 (en) 2017-10-23 2024-02-15 Boehringer Ingelheim International Gmbh New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
WO2023104958A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
WO2023104961A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
WO2024068386A1 (en) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US456685A (en) * 1891-07-28 Automatic electric gas-lighter
DE3323932A1 (de) * 1983-07-02 1985-01-10 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
DE3540952A1 (de) * 1985-11-19 1987-05-21 Thomae Gmbh Dr K Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
JP2002533464A (ja) 1998-12-28 2002-10-08 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント プテリジン誘導体の免疫抑制作用
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DE10202468A1 (de) 2002-01-23 2004-09-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung
DE102004057645A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
DE102004057618A1 (de) 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US456685A (en) * 1891-07-28 Automatic electric gas-lighter
DE3323932A1 (de) * 1983-07-02 1985-01-10 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel
DE3540952A1 (de) * 1985-11-19 1987-05-21 Thomae Gmbh Dr K Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MERZ, K.-H. ET AL.: "Synthesis of 7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidinopterid ine and Novel Derivatives Free of Positional Isomers. Potent Inhibitors of cAMP-Specific Phosphodiesterase and of Malignant Tumor Cell Growth", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 24, 1998, pages 4733 - 4743, XP002239611, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
DE102004057595A1 (de) 2006-06-08
CA2587269A1 (en) 2006-08-06
JP2008521774A (ja) 2008-06-26
WO2006058869A8 (de) 2007-01-18
EP1824854A2 (de) 2007-08-29
US7750009B2 (en) 2010-07-06
WO2006058869A2 (de) 2006-06-08
AR054991A1 (es) 2007-08-01
TW200635597A (en) 2006-10-16
US20060116373A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
WO2006058869A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2006058867A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2006056607A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2007135026A3 (de) Substituierte pteridine als therapeutika
WO2006025991A3 (en) Isoindoline compounds and methods of making and using the same
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
WO2005046603A3 (en) Pyridine compounds
ATE549338T1 (de) Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
WO2006034154A3 (en) Salts of 5-azacytidine
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
TW200628473A (en) Novel heterocycles
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
WO2007052023A3 (en) Novel compounds
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
WO2008007211A8 (en) Substituted n-bicyclicalkyl bicyclic carboxyamide compounds
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2007068750A3 (en) Immunoglobulins directed against nogo
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
WO2006135694A3 (en) Uii-modulating compounds and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2587269

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005823962

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007541995

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005823962

Country of ref document: EP